1
|
McLeod SM, Carter NM, Huband MD, Traczewski MM, Bradford PA, Miller AA. Sulbactam-durlobactam susceptibility test method development and quality control ranges for MIC and disk diffusion tests. J Clin Microbiol 2024; 62:e0122823. [PMID: 38095417 PMCID: PMC10793306 DOI: 10.1128/jcm.01228-23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2023] [Accepted: 11/06/2023] [Indexed: 01/18/2024] Open
Abstract
Sulbactam-durlobactam is a β-lactam/β-lactamase inhibitor combination developed to treat hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter baumannii-calcoaceticus complex (ABC). Durlobactam is a diazabicyclooctane β-lactamase inhibitor with potent activity against Ambler classes A, C, and D serine β-lactamases and restores sulbactam activity against multidrug-resistant ABC. Studies were conducted to establish sulbactam-durlobactam antimicrobial susceptibility testing methods for both broth microdilution minimal inhibitory concentration (MIC) and disk diffusion tests as well as quality control (QC) ranges. To establish the MIC test method, combinations of sulbactam and durlobactam were evaluated using a panel of genetically characterized A. baumannii isolates which were categorized as predicted to be susceptible or resistant based on the spectrum of β-lactamase inhibition by durlobactam. MIC testing with doubling dilutions of sulbactam with a fixed concentration of 4 µg/mL of durlobactam resulted in the greatest discrimination of the pre-defined susceptible and resistant strains. Similarly, the sulbactam/durlobactam 10/10 µg disk concentration showed the best discrimination as well as correlation with the MIC test. A. baumannii NCTC 13304 was selected for QC purposes because it assesses the activity of both sulbactam and durlobactam with clear endpoints. Multi-laboratory QC studies were conducted according to CLSI M23 Tier 2 criteria. A sulbactam-durlobactam broth MIC QC range of 0.5/4-2/4 µg/mL and a zone diameter QC range of 24-30 mm were determined for A. baumannii NCTC 13304 and have been approved by CLSI. These studies will enable clinical laboratories to perform susceptibility tests with accurate and reproducible methods.
Collapse
Affiliation(s)
- Sarah M. McLeod
- Entasis Therapeutics Inc. (an affiliate of Innoviva Specialty Therapeutics, Inc.), Waltham, Massachusetts, USA
| | - Nicole M. Carter
- Entasis Therapeutics Inc. (an affiliate of Innoviva Specialty Therapeutics, Inc.), Waltham, Massachusetts, USA
| | | | | | | | - Alita A. Miller
- Entasis Therapeutics Inc. (an affiliate of Innoviva Specialty Therapeutics, Inc.), Waltham, Massachusetts, USA
| |
Collapse
|
2
|
Haddad N, Ajaz J, Mansour L, Kasemodel R, Jarvis J, Jarad J, Gorski H, Carr M. A Review of the Clinical Utilization of Oral Antibacterial Therapy in the Treatment of Bone Infections in Adults. Antibiotics (Basel) 2023; 13:4. [PMID: 38275315 PMCID: PMC10812599 DOI: 10.3390/antibiotics13010004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2023] [Revised: 12/12/2023] [Accepted: 12/14/2023] [Indexed: 01/27/2024] Open
Abstract
Chronic osteomyelitis in adults is managed with prolonged courses of intravenous antibiotics in conjunction with surgical debridement of necrotic bone. Over the past 40 years, there has been no paradigm shift in this approach, as randomized controlled trials of this standard of care compared to alternatives such as prolonged oral antibiotics are scarce. However, there have been many small trials, case reports, and review papers evaluating the effectiveness of oral treatment for chronic osteomyelitis. The oral route for infections requiring prolonged treatment is intuitively and practically more favorable due to several advantages, the most important of which is the avoidance of long-term IV antimicrobial therapy with its complications, inconvenience, and cost. In this paper, we review the literature evaluating oral antibiotic therapy in the management of chronic bone infections since 1975. The majority of osteomyelitis infections are caused by Staphylococcus aureus, hence we focus on its treatment using oral antibiotics; however, we also emphasize subpopulations of patients with diabetes, implanted hardware, and with less common bacterial organisms. The primary objective of this review is to promulgate clinical recommendations on the use of oral antibiotics in bone infections in the context of initial therapy, transition from intravenous therapy, and the role of chronic suppression. The secondary objective is to summarize current knowledge of the specific oral antimicrobial agents that are commonly utilized, together with a synopsis of the available literature pertaining to their pharmacokinetic/pharmacodynamic properties and duration of therapy in bone infection.
Collapse
Affiliation(s)
- Nicholas Haddad
- College of Medicine, Central Michigan University, 1632 Stone St., Saginaw, MI 48603, USA
- CMU Medical Education Partners, Internal Medicine Residency Program, Central Michigan University, 1000 Houghton Ave., Saginaw, MI 48602, USA; (J.A.); (R.K.); (J.J.)
| | - Jibran Ajaz
- CMU Medical Education Partners, Internal Medicine Residency Program, Central Michigan University, 1000 Houghton Ave., Saginaw, MI 48602, USA; (J.A.); (R.K.); (J.J.)
| | - Lina Mansour
- Covenant HealthCare, 1447 N. Harrison St., Saginaw, MI 48602, USA; (L.M.); (M.C.)
| | - Robert Kasemodel
- CMU Medical Education Partners, Internal Medicine Residency Program, Central Michigan University, 1000 Houghton Ave., Saginaw, MI 48602, USA; (J.A.); (R.K.); (J.J.)
| | - Jennifer Jarvis
- Ascension St. Mary’s Hospital, 800 S. Washington Ave., Saginaw, MI 48601, USA;
| | - John Jarad
- CMU Medical Education Partners, Internal Medicine Residency Program, Central Michigan University, 1000 Houghton Ave., Saginaw, MI 48602, USA; (J.A.); (R.K.); (J.J.)
| | - Haley Gorski
- McLaren Bay Region, 1900 Columbus Ave., Bay City, MI 48708, USA;
| | - Maddie Carr
- Covenant HealthCare, 1447 N. Harrison St., Saginaw, MI 48602, USA; (L.M.); (M.C.)
| |
Collapse
|
3
|
A Systematic Approach to the Selection of the Appropriate Avibactam Concentration for Use with Ceftazidime in Broth Microdilution Susceptibility Testing. Antimicrob Agents Chemother 2018; 62:AAC.00223-18. [PMID: 29735568 DOI: 10.1128/aac.00223-18] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2018] [Accepted: 05/03/2018] [Indexed: 11/20/2022] Open
Abstract
Selection of the avibactam concentration to combine with ceftazidime in susceptibility testing was determined using Gram-negative isolates with characterized β-lactamases predefined as susceptible or resistant, based on the known inhibition spectrum of avibactam. MIC values were determined by broth microdilution of ceftazidime with fixed concentrations and ratios of avibactam. A constant concentration of 4 μg/ml of avibactam was selected for susceptibility testing with ceftazidime because of its ability to correctly categorize susceptible and resistant isolates while minimizing categorical errors.
Collapse
|
4
|
Hung MN, Hsueh PR, Chang HT, Lee WS, Chou MY, Chen IS, Wang JH, Lin CF, Shyr JM, Ko WC, Wu JJ, Liu YC, Huang WK, Teng LJ, Liu CY, Luh KT. In vitro activities of various piperacillin and sulbactam combinations against bacterial pathogens isolated from Intensive Care Units in Taiwan: SMART 2004 programme data. Int J Antimicrob Agents 2006; 29:145-52. [PMID: 16815690 DOI: 10.1016/j.ijantimicag.2006.02.017] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2005] [Accepted: 02/13/2006] [Indexed: 11/20/2022]
Abstract
We investigated the in vitro activity of various piperacillin and sulbactam combinations against Gram-negative bacterial isolates from Intensive Care Units (ICUs) in Taiwan. Antimicrobial susceptibility testing of 1030 bacterial isolates recovered from ICUs of nine major teaching hospitals was performed using the agar dilution method. Sulbactam was added to piperacillin either at a fixed sulbactam concentration of 4 mg/L and 8 mg/L or at a piperacillin:sulbactam ratio of 2:1 and 4:1. Piperacillin/sulbactam at a ratio of 2:1 or a fixed 8 mg/L concentration of sulbactam had better activities against Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis and Serratia marcescens than other piperacillin/sulbactam formulations. For Pseudomonas aeruginosa, piperacillin/sulbactam (2:1 or 4:1 ratios) had MIC(90) values (minimum inhibitory concentration for 90% of the organisms) of 64 mg/L (>90% susceptibility) compared with 64 mg/L for cefoperazone/sulbactam (68% susceptibility) and 128 mg/L for piperacillin/tazobactam (82% susceptibility). For Acinetobacter baumannii, both piperacillin/sulbactam (either 2:1 ratio or a fixed 8 mg/L sulbactam) and cefoperazone/sulbactam were the most potent agents. Adding sulbactam to piperacillin resulted in increased susceptibility rates among piperacillin-resistant P. aeruginosa (53-57% in either 2:1 or 4:1 ratios) and A. baumannii (38-46% in either 2:1 ratio or a fixed 8 mg/L concentration of sulbactam) isolates. Results of susceptibility tests with piperacillin/sulbactam are dependent on the method used. Piperacillin/sulbactam combinations possessed better in vitro activities than piperacillin alone or piperacillin/tazobactam against P. aeruginosa and A. baumannii.
Collapse
Affiliation(s)
- Min-Nan Hung
- Departments of Laboratory Medicine and Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Cawley MJ, Suh C, Lee S, Ackerman BH. Nontraditional dosing of ampicillin-sulbactam for multidrug-resistant Acinetobacter baumannii meningitis. Pharmacotherapy 2002; 22:527-32. [PMID: 11939689 DOI: 10.1592/phco.22.7.527.33676] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
A 52-year-old man was admitted to a local hospital with headache, nausea, vomiting, dizziness, photophobia, and confusion after a sudden fall. Progressive changes in neurologic function were noted despite neurosurgical intervention and broad-spectrum antimicrobial coverage. Cerebral spinal fluid (CSF) culture identified Acinetobacter baumannii that was resistant to traditionally recommended therapies of amikacin and imipenem-cilastatin. The organism demonstrated minimum inhibitory concentrations of greater than 32 microg/ml and 8 microg/ml, respectively, for these two agents. Ampicillin 2 g-sulbactam 1 g every 3 hours was administered based on history of therapeutic failure of traditional dosing in our thermal injury population. Repeat CSF cultures after 12 days of ampicillin-sulbactam therapy were negative. After 35 days, the patient's A. baumannii infection was completely resolved. The patient experienced no adverse drug events or toxicity with this high-dosage regimen.
Collapse
Affiliation(s)
- Michael J Cawley
- Department of Pharmacy Practice and Pharmacy Administration, Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, Pennsylvania 19104-4495, USA.
| | | | | | | |
Collapse
|
6
|
Lode H. Role of sultamicillin and ampicillin/sulbactam in the treatment of upper and lower bacterial respiratory tract infections. Int J Antimicrob Agents 2001; 18:199-209. [PMID: 11673031 DOI: 10.1016/s0924-8579(01)00387-9] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
The emergence of beta-lactamase-mediated resistance to beta-lactam antibiotics among key respiratory tract pathogens has threatened the usefulness of the beta-lactam agents familiar to physicians as being clinically effective and well tolerated. This article reassesses the clinical usefulness of ampicillin when administered in combination with the beta-lactamase inhibitor sulbactam, either intravenously or orally (as the mutual prodrug sultamicillin), in the treatment of upper and lower respiratory tract infections. Numerous clinical studies and several meta-analyses indicate that ampicillin/sulbactam and sultamicillin are clinically effective and well tolerated in both adults and children, in agreement with published North American and European guidelines.
Collapse
Affiliation(s)
- H Lode
- Pneumologie I (Infektiologie and Immunologie), Lungenklinik Heckeshorn, Zum Heckeshorn 33, 14109 Berlin, Germany.
| |
Collapse
|
7
|
McKinnon PS, Neuhauser MM. Efficacy and cost of ampicillin-sulbactam and ticarcillin-clavulanate in the treatment of hospitalized patients with bacterial infections. Pharmacotherapy 1999; 19:724-33. [PMID: 10391418 DOI: 10.1592/phco.19.9.724.31537] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
STUDY OBJECTIVE To evaluate the efficacy and cost of treatment with two beta-lactam/beta-lactamase-inhibitor combinations. DESIGN Retrospective, open-label multicenter study. SETTING Fifty-four hospitals across the United States. PATIENTS Eight hundred ninety patients with skin and soft tissue, intraabdominal, gynecologic, respiratory, urinary tract, or other infections that required parenteral antibiotic therapy. INTERVENTION Patients were administered either ampicillin-sulbactam 1.5 or 3.0 g every 6 hours or ticarcillin-clavulanate 3.1 g every 6 hours. MEASUREMENTS AND MAIN RESULTS The agents did not differ significantly in efficacy for most infections; although, ampicillin-sulbactam was bacteriologically superior to ticarcillin-clavulanate in the treatment of intraabdominal infections (p=0.0011). Costs of ampicillin-sulbactam, particularly the 1.5-g dose, were lower than those of ticarcillin-clavulanate for skin and soft tissue (p<0.001), intraabdominal (p=0.005), and respiratory tract (p<0.001) infections. CONCLUSION Ampicillin-sulbactam provides effective coverage for patients with the above infections and is as effective as the broader-spectrum agent.
Collapse
Affiliation(s)
- P S McKinnon
- Department of Pharmacy Services, Detroit Receiving Hospital and University Health Center, Michigan 48201, USA
| | | |
Collapse
|
8
|
Jones RN, Dudley MN. Microbiologic and pharmacodynamic principals applied to the antimicrobial susceptibility testing of ampicillin/sulbactam: analysis of the correlations between in vitro test results and clinical response. Diagn Microbiol Infect Dis 1997; 28:5-18. [PMID: 9218913 DOI: 10.1016/s0732-8893(97)00013-8] [Citation(s) in RCA: 25] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
The correlation between various ampicillin/sulbactam in vitro antimicrobial susceptibility test results and the clinical outcome of patients treated with this agent have been examined. A survey of over 29,000 clinical isolates of the family Enterobacteriaceae found that the proportion of susceptible pathogens as assessed by current susceptibility testing interpretive guidelines (NCCLS) for disk diffusion and dilution (MIC) assays was significantly less than the proportion of patients cured or clinically improved in ampicillin/sulbactam clinical trials. Also, the results of two NCCLS methods differ greatly in the perceived percentages of susceptible strains (63.9% versus 72.2%; unacceptable variation). Furthermore, the current interpretive criteria resulted in high false-susceptible (4.2%) and total (19.7%) error rates. When proposed interpretive guidelines were applied, approximately 73 to 87% of the Enterobacteriaceae strains were observed to be susceptible, the variation between methods was minimized, and the error rates were reduced. A retrospective analysis of data from clinical trials with ampicillin/sulbactam indicated that the proportion of patients who were cured or clinically improved and bacterially eradicated was not appreciably different in patients having baseline Enterobacteriaceae pathogens with MICs of 16 or 32 micrograms/ml (ampicillin MIC component) as compared to those with pathogens having MICs of < or = 8 micrograms/ml. Studies in animals, in vitro models, and pharmacokinetic considerations indicate that a change in the MIC breakpoint for ampicillin/sulbactam should be considered. The proposed interpretive guideline revisions for ampicillin/sulbactam susceptibility testing of the Enterobacteriaceae were 1) use current diagnostic reagents with criteria of < or = 16/8 micrograms/ml (> or = 14 mm) as susceptible and > or = 64/32 micrograms/ml (< or = 10 mm) as resistant; e.g., 75.9 to 76.0% spectrum and 1.3% false-susceptible error; 2) use alternative diagnostic reagents (1:1 ratio MIC; 20/20 micrograms disks) with criteria of < or = 8/8 micrograms/ml (> or = 18 mm) as susceptible and > or = 32/32 micrograms/ml (< or = 14 mm) as resistant; e.g., 73.3 to 76.9% spectrum and 1.8% false-susceptible error; or 3) use alternative diagnostic reagents with criteria of < or = 16/16 micrograms/ml (> or = 14 mm) as susceptible and > or = 64/64 micrograms/ml (< or = 10 mm) as resistant; e.g., 84.7 to 86.9% spectrum and 1.3% false-susceptible error. Data from a comprehensive in vitro survey of clinical isolates, retrospective analyses of clinical trials, and studies of animal models support the modification of contemporary interpretive guidelines for ampicillin/sulbactam antimicrobial susceptibility tests. The best short-term criteria would apply current in vitro diagnostic reagents and a modified susceptible breakpoint (< or = 16/8 micrograms/ml as susceptible; option 1 above) until new diagnostic reagents can be qualified by means of studies needed for quality assurance of standardized methods (NCCLS M23-A and FDA procedures). These changes would provide a better in vitro prediction of ampicillin/sulbactam efficacy in clinical practice.
Collapse
Affiliation(s)
- R N Jones
- Department of Pathology, University of Iowa College of Medicine, Iowa City 52242, USA
| | | |
Collapse
|
9
|
Lode H. Clinical indications for β-lactamase inhibitors in comparison to other antibiotics. Int J Antimicrob Agents 1996; 7 Suppl 1:S3-7. [DOI: 10.1016/0924-8579(96)00312-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
10
|
|
11
|
Kumarasinghe G, Chow C, Koh BL, Chiang KL, Liew HY, Ti TY. Antimicrobial resistance problem in a university hospital. Pathology 1995; 27:67-70. [PMID: 7603757 DOI: 10.1080/00313029500169502] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
In a study conducted in 1991 in the National University Hospital, Singapore, the susceptibilities of a total of 2156 recent clinical isolates were tested against 25 antimicrobial drugs. The organisms were those isolated from routine specimens received in the microbiology laboratory. About 40% Staphylococcus aureus isolations in the hospital were resistant to methicillin. A high incidence of the resistance was noted among Staphylococcus aureus and coagulase negative staphylococci to antistaphylococcal drugs. Acinetobacter sp. and Klebsiella sp. are becoming major threats with regard to antimicrobial treatment as they are multi-drug resistant. Pseudomonas aeruginosa did not show a resistance problem except to pefloxacin (74%). Ampicillin resistance of Acinetobacter sp. (93%) was reduced to 71% by ampicillin/clavulanic acid and to 7% by ampicillin/sulbactam. With regards to the urinary isolates higher rates of resistance were noticed with Pseudomonas aeruginosa to antipseudomonas drugs and for co-trimoxazole with other Gram negative organisms, compared to non-urinary isolates.
Collapse
Affiliation(s)
- G Kumarasinghe
- Department of Laboratory Medicine, National University Hospital, Singapore
| | | | | | | | | | | |
Collapse
|
12
|
Activité inhibitrice de différentes concentrations d'acide clavulanique, de tazobactam et de sulbactam vis-à-vis de 117 souches d'entérobactéries productrices de β-lactamase. Med Mal Infect 1993. [DOI: 10.1016/s0399-077x(05)80510-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
13
|
Sanders CC, Thomson KS, Bradford PA. PROBLEMS WITH DETECTION OF β-LACTAM RESISTANCE AMONG NONFASTIDIOUS GRAM-NEGATIVE BACILLI. Infect Dis Clin North Am 1993. [DOI: 10.1016/s0891-5520(20)30529-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
14
|
Akova M, Akalìn HE, Korten V, Ozgen T, Erbengi A. Treatment of intracranial abscesses: experience with sulbactam/ampicillin. J Chemother 1993; 5:181-5. [PMID: 8371128 DOI: 10.1080/1120009x.1993.11739230] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
In an open prospective study, the efficacy of sulbactam/ampicillin (50 and 100 mg/kg, respectively, qid) was evaluated in 21 patients with intracranial abscess(es). Sixteen patients had cerebral, 3 epidural, and 2 cerebellar abscesses. Multiple lesions were found in 7 patients. Sixteen patients underwent surgical intervention, others were treated with antibiotic alone. The mean duration of antibiotic therapy (+/- SD) was 48 +/- 10 days (range 26-65 days). The mean duration of follow-up after completion of therapy (+/- SD) was 6 +/- 2.4 months. All patients had at least some reduction in size of abscess(es) within 3 weeks of the initiation of therapy as monitored by computerized tomography. Seventeen patients were cured, three patients died due to causes unrelated to their infection. One patient was reoperated since no clear improvement either clinically or radiologically was observed 18 days after the first operation. Side effects of sulbactam/ampicillin were minor and transient. Results obtained in this study indicate that sulbactam/ampicillin can be used in the treatment of intracranial abscesses, alone or with surgical intervention.
Collapse
Affiliation(s)
- M Akova
- Hacettepe University School of Medicine, Department of Medicine, Ankara, Turkey
| | | | | | | | | |
Collapse
|
15
|
Pfaller MA, Barry AL, Fuchs PC, Gerlach EH, Hardy DJ, McLaughlin JC. Comparison of fixed concentration and fixed ratio options for dilution susceptibility testing of gram-negative bacilli to ampicillin and ampicillin/sulbactam. Eur J Clin Microbiol Infect Dis 1993; 12:356-62. [PMID: 8354303 DOI: 10.1007/bf01964434] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
Ampicillin combined with sulbactam was tested at both fixed ratio (2:1 and 1:1) and fixed sulbactam concentrations (4 micrograms/ml, 8 micrograms/ml and 16 micrograms/ml) against 2440 consecutively isolated gram-negative bacilli. Sulbactam significantly enhanced the spectrum of ampicillin activity. Overall, at 8 micrograms/ml ampicillin inhibited 50% of the Enterobacteriaceae isolates, whereas 69% to 84% of the isolates were inhibited by the various sulbactam combinations. The widest spectrum of activity for ampicillin/sulbactam was achieved by testing at a fixed sulbactam concentration of 16 micrograms/ml, followed by the 1:1 ratio and the fixed 8 micrograms/ml (84%, 76% and 74% inhibited, respectively). The amount of sulbactam at the susceptible breakpoint concentrations of ampicillin markedly affected the percentage of susceptible strains. Combinations that include 8 micrograms/ml of sulbactam are suggested for consideration.
Collapse
Affiliation(s)
- M A Pfaller
- Department of Pathology L471, Oregon Health Sciences University, Portland 97201
| | | | | | | | | | | |
Collapse
|
16
|
De Simone C, Chiodo F, Delia S, Pastore G, Scalise G, Sorice F, Tonietti G, Zanussi C, Paoloni M, Gargiulo M. Clinical results of a multicenter study with sulbactam/ampicillin for the treatment of patients with lower respiratory and urinary tract infections. J Chemother 1991; 3:321-7. [PMID: 1809811 DOI: 10.1080/1120009x.1991.11739113] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
A total of 124 patients with lower respiratory tract (44) or urinary tract infections (80) were enrolled in an open, multicenter study to evaluate the efficacy and tolerability of sulbactam/ampicillin, administered at the dosage of 3 g/die by intramuscular route. Pretreatment pathogens from patients with lower respiratory tract infections included: Streptococcus alpha-haemolyticus in 8 cases, Streptococcus beta-haemolyticus in 2 cases, Staphylococcus albus in 7 cases, Haemophilus influenzae in 7 cases, Staphylococcus aureus in 6 cases, Klebsiella oxytoca in 5 cases, Staphylococcus epidermidis in 3 cases, Streptococcus pneumoniae in 3 cases, Escherichia coli in 2 cases; in one subject (2.75%), no microorganisms were isolated. In vitro, 36 isolates (84%) were sensitive to SA and 7 (16%) were resistant. At the end of therapy, all the causative pathogens sensitive to sulbactam/ampicillin were eliminated. In patients with urinary tract infections, pretreatment pathogens were: E. coli in 40 cases, S. albus in 16 cases, Proteus mirabilis in 8 cases, Enterobacter agglomerans in 6 cases, Proteus vulgaris in 3 cases, Streptococcus faecalis in 3 cases, Streptococcus liquefaciens in 2 cases, Pseudomonas aeruginosa in 2 cases. In vitro, 64 isolates (80%) were sensitive to sulbactam/ampicillin and 16 (20%) were resistant. At the end of therapy, 63 out of the 64 pathogens sensitive to sulbactam/ampicillin were eliminated; in one case the therapy was interrupted due to adverse effect. Clinical efficacy: in subjects with lower respiratory tract infections, sulbactam/ampicillin cured 32 patients (72.72%) and ameliorated the clinical status of 8 patients (18.18%); efficacy rate: 90.9%).(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- C De Simone
- Malattie Infettive, Università dell'Aquila, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Stefani S, Castiglia P, Maida A, Muresu E, Mezzatesta ML, Nicoletti G. Comparative in-vitro activity of piperacillin and piperacillin plus tazobactam towards beta-lactamase producing clinical isolates. J Chemother 1990; 2:295-9. [PMID: 1965317 DOI: 10.1080/1120009x.1990.11739032] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
The authors evaluated the in-vitro antibacterial activity of piperacillin alone and of piperacillin combined with tazobactam, a new beta-lactamase inhibitor, on 398 clinical isolates, both Gram-positive and Gram-negative. The piperacillin/tazobactam combination was evaluated in the fixed ratio 8:1. The vast majority of the microorganisms tested had reduced susceptibility to piperacillin (minimum inhibitory concentration (MIC) range 0.12- greater than 256 mg/l) due to beta-lactamase production. The following results were obtained: against Haemophilus influenzae, tazobactam was effective in reducing the MICs of piperacillin by 512 fold. The activity of piperacillin/tazobactam was lower against Pseudomonas sp., while some activity was demonstrated against some strains of Klebsiella. Good activity was seen not only against methicillin-susceptible (MS) staphylococci but also against some methicillin-resistant (MR) strains. In the latter, the combination of piperacillin/tazobactam was active only if the strains showed beta-lactamase production. These findings are interesting above all in regard to the synergistic effect demonstrated against MR beta-lactamase producing staphylococci and the Klebsiella-Enterobacter-Serratia (KES) group.
Collapse
Affiliation(s)
- S Stefani
- Institute of Microbiology, University of Catania, Italy
| | | | | | | | | | | |
Collapse
|
18
|
Kazmierczak A, Pechinot A, Siebor E, Cordin X, Labia R. Sulbactam: secondary mechanisms of action. Diagn Microbiol Infect Dis 1989; 12:139S-146S. [PMID: 2591173 DOI: 10.1016/0732-8893(89)90126-0] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Light and scanning electron microscopy showed that 0.25, 0.5 and 1 times the minimum inhibitory concentrations (MICs) of sulbactam (SULB) caused filament formation in different species of Enterobacteriaceae, while 2 and 4 times the MICs caused spheroplast formation and subsequent lysis. By using a competitive assay with 125I-penicillin X, SULB showed a primary affinity for the PBP 1a and PBP3 of Escherichia coli, as well as for the PBP1a of Proteus mirabilis. The bactericidal interaction of human polymorphonuclear leukocytes (PMN) and SULB against E. coli K-1 resistant to the bactericidal activity of human serum was studied in vitro; however, SULB concentrations showed variations in the medium according to human kinetic data. Under these conditions, bacterial growth occurred in Hanks balanced salt solution containing SULB, PMN, or SULB-PMN in combination. In addition, bactericidal activity was observed in serum, with a killing rate of 90% for PMN or SULB, and 95% for SULB-PMN in combination. The postantibiotic enhancement of PMN bactericidal function was assessed against E. coli K1 pretreated with 0.5 the MIC of SULB (32 micrograms/ml) for 0.5 hr. The 90% bacterial killing rate of PMN occurred by 1.5 hr for pretreated bacteria and by 2.5 hr for untreated bacteria. Furthermore, the luminol-enhanced chemiluminescence (CL) assay using an E. coli stimulus showed that SULB does not modify PMN activity.
Collapse
|
19
|
|